Lymph Nodes News and Research

RSS

AI can help with the diagnosis of B-cell lymphomas and related leukemias

The presence of cancer of the lymphatic system is often determined by analyzing samples from the blood or bone marrow.

18 Sep 2021

New imaging technique can change the landscape of prostate cancer detection and treatment

Prostate-specific membrane antigen, or PSMA, -targeted PET imaging for prostate cancer has been a breakthrough diagnosis tool in locating prostate cancer tumors for more precise treatment.

16 Sep 2021

COVID-19 and the gut-lung axis

A new study explores the hypothesis that stimulation of the gut could be responsible for the lung inflammation seen in COVID-19, triggered by SARS-CoV-2.

16 Sep 2021

Researchers identify the spleen as primary site for priming of 'killer' T cells during influenza infection

CD8+ T cells - known as "killer" T cells - are the assassins of the immune system. Once they are primed, they seek out and destroy other cells that are infected with virus or cells that are cancerous.

12 Sep 2021

NIH researchers develop a detailed cellular map of chronic MS lesions

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms of the disease.

10 Sep 2021

Simple, non-invasive tool obviates unnecessary surgery in patients with colorectal cancer

A blood RNA test predicts whether residual tumour cells remain in early-stage colon cancer patients and obviates unnecessary surgery.

6 Sep 2021

Stem-like T cells within certain lymph nodes could be natural cancer fighters, study shows

In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.

3 Sep 2021

Research uncovers test to identify iMCD patients with superior response to FDA-approved treatment

New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.

2 Sep 2021

Immune cells present in tumors from head and neck cancer patients, study reports

A new study from scientists at Emory Vaccine Center and Winship Cancer Institute of Emory University reports that the immune cells that are the major targets of immune checkpoint inhibitors are present in tumors from head and neck cancer patients.

2 Sep 2021

Study examines safety of COVID-19 vaccine in a nationwide mass-vaccination setting

The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the safety of the Pfizer/BioNTech BNT162B2 vaccine against COVID-19.

27 Aug 2021

Parts of Lake Tahoe close after chipmunks test positive for plague

Officials are closing some areas on the south shore of Lake Tahoe after some chipmunks tested positive for plague, an infectious disease that affects both humans and other mammals.

4 Aug 2021

Hormone-resistant prostate, breast cancers added to clinical trial of experimental DNA therapy

The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology's Elenagen, an experimental DNA therapy, to include two new arms: 1) hormone-resistant breast cancer; and 2) hormone-resistant metastatic prostate cancer.

3 Aug 2021

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Scientists in the Netherlands recently conducted an open-level, randomized-controlled trial to evaluate the safety and immunogenicity of fractional intradermal doses of the mRNA-based COVID-19 vaccine mRNA-1273 (Moderna). The trial findings reveal that the fractional dose regimen of the Moderna vaccine is well tolerated and safe and is capable of inducing robust antibody responses in vaccine recipients. The study is currently available on the medRxiv* preprint server.

2 Aug 2021

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma.

23 Jul 2021

CDC monitoring over 200 individuals possibly exposed to monkeypox

The United States Centers for Disease Control and Prevention (CDC) is monitoring over 200 people who may have been exposed to the monkeypox virus.

22 Jul 2021

Study shows promise of combining radiation therapy with dendritic-cell vaccines for breast cancer

A research team led by Fumito Ito, MD, PhD, FACS, of Roswell Park Comprehensive Cancer Center reports new data on the promise of combining standard treatment for breast cancer with a particular form of cancer immmunotherapy - dendritic-cell (DC) treatment vaccines.

20 Jul 2021

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

The ongoing coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 190 million cases worldwide. Of these, over 4 million have died due to the infection.

20 Jul 2021

Novel robotic neck brace may help doctors to analyze neck mobility in cancer patients

A new robotic neck brace from researchers at Columbia Engineering and their colleagues at Columbia's Department of Otolaryngology may help doctors analyze the impact of cancer treatments on the neck mobility of patients and guide their recovery.

19 Jul 2021

UCSF researchers discover how the immune system may play a role in miscarriage

Researchers at UC San Francisco are zeroing in on how the immune system may play a role in miscarriage, which affects about a quarter of pregnancies.

16 Jul 2021

Early B cell signatures predict antibody responses to mRNA-based COVID-19 vaccine

Researchers in the United States have identified both antigen-specific and antigen non-specific predictive signatures of antibody responses to Moderna’s two-dose coronavirus disease 2019 (COVID-19) vaccine that protects against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021